StreetAlpha.app
Home › Stocks › CADL

Candel Therapeutics, Inc. (CADL)

$5.04
▼ −1.75%
LAST CLOSE · NOV 20

Candel Therapeutics develops viral immunotherapies that are injected into tumors to fight cancer. It last closed at $5.04 on Nov 20, down 1.75% on the day. The next earnings report for CADL is expected around Thu, Feb 18, 2027, after the close. For the quarter ended Sep 2026, CADL reported EPS of -$0.28. Over its last 8 reports the stock moved an average of 10.2% the session after earnings. Over the last 12 months CADL insiders bought $3.0M of stock on the open market and sold $3.6M, according to SEC Form 4 filings.

AI Auto Pilots
Is CADL in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CADL.

Key Stats

Last 12 months
Results
Net income
−$99.1M
EPS (diluted)
−$1.53
Free cash flow
−$70.2M
Valuation
Market cap
$395.4M
78.4M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$203.1M
At Sep 30
Shareholder equity
$131.6M
Shares outstanding
78.4M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$36.1M−$36.1MFY2021FY2022: −$18.8M−$18.8MFY2022FY2023: −$37.9M−$37.9MFY2023FY2024: −$55.2M−$55.2MFY2024FY2025: −$38.2M−$38.2MFY2025

From CADL's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Feb 18
Estimated date · After the close
Reported EPS
-$0.28
Quarter ended Sep 2026
Year ago EPS
-$0.21
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.39Dec '24Mar 2025: $0.13Mar '25Jun 2025: -$0.09Jun '25Sep 2025: -$0.21Sep '25Dec 2025: -$0.55Dec '25Mar 2026: -$0.14Mar '26Jun 2026: -$0.52Jun '26Sep 2026: -$0.28Sep '26Latest -$0.28
Revenue by quarter
Not enough quarters on file yet.
How CADL moved after its last 8 reports
Average move the session after a report ±10.2%
Nov 12, 2026After the close−26.1%
Aug 13, 2026Time not announced+10.5%
May 14, 2026Time not announced−0.3%
Feb 19, 2026After the close−14.2%
Nov 13, 2025Time not announced−6.3%
Oct 14, 2025Time not announced−10.7%
Aug 14, 2025Time not announced−5.6%
May 13, 2025Time not announced+7.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CADLStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on CADL
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CADL

Technical Analysis

CADL · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 53% below its 20 day and 81% below its 50 day average. It is 67% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 26), oversold. The nearest support is the Pivot S1 at $4.86, and the nearest resistance the Pivot at $5.08.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 14.4%/day
Key levels
$14.0052 week high+177.8%
$10.10100 day average+100.4%
$9.1050 day average+80.6%
$8.93Swing high (Oct 29)+77.2%
$8.40200 day average+66.7%
$7.6920 day average+52.6%
$5.27Pivot R1+4.6%
$5.08Pivot+0.8%
$5.04Last close
$4.86Pivot S1−3.6%
$4.3552 week low−13.7%
Indicators
RSI (14)26.00Oversold below 30Oversold
MACD-1.06Below its signal lineBearish
Stochastic2.2Near the bottom of its rangeOversold
ADX (14)37.0Trending down
Williams %R-97.2Oversold below −80, overbought above −20Oversold
CCI (20)-134.3Oversold below −100, overbought above 100Oversold
Rate of change−42.4%Change over 10 sessionsBearish
ATR (14)$0.72Typical daily range, 14.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CADL

What happened before

See how CADL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow CADL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How CADL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for CADLHow many large options trades hit CADL, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

CADL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲92 buying vs 42 selling
  • ▲Held by funds +0.7 pts
  • ▲Funds holding +3
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding141138+2.2%
In funds' top 10220.0%
Held by funds65.0%64.2%+0.7 pts
New / increased22 / 7040 / 62−9.8%
Reduced / sold out21 / 2123 / 13+16.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CADL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CADL Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$3.0M1 buy · 1 insider
Sold$3.6M4 sales · 3 insiders
100% of the selling was under pre-arranged trading plans.
2026-02 bought $3.0M2026-06 sold $306K2026-08 sold $84K2026-09 sold $3.2MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 11Paul Peter TakCEOSale plan280,245$11.28$3.2M
Aug 17Seshu TyagarajanChief Technology OfficerSale plan7,000$12.00$84K
Jun 29Francesca BaroneChief Scientific OfficerSale plan23,447$10.06$236K
Jun 29Seshu TyagarajanChief Technology OfficerSale plan7,000$10.02$70K
Feb 23Paul B ManningDirectorBuy550,458$5.45$3.0M
Jul 28, 2025William Garrett NicholsChief Medical OfficerSale plan937$6.98$7K
Every insider buy and sale for CADL over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CADL insider trades →

From SEC Form 4 filings by CADL's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CADL is in one of them and how their past CADL trades turned out.

CADL in the AI portfolios
Loading…

CADL News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CADL in an article yet. Here's the latest on the wider market.

CADL in the news

About Candel Therapeutics

Candel Therapeutics is a clinical stage biopharmaceutical company based in Needham, Massachusetts. It develops viral immunotherapies for cancer, which are engineered viruses injected directly into tumors to stimulate the body's immune system against cancer. Its lead candidate, aglatimagene besadenovec, is being studied mainly for localized prostate cancer and for lung cancer. Its treatments are aimed at patients with a range of solid tumors.

Headquarters
Needham, MA